SAM 101

Drug Profile

SAM 101

Alternative Names: Antipsychotics/minocycline; Minocycline/antipsychotics; SAM-101

Latest Information Update: 05 Jan 2016

Price : $50

At a glance

  • Originator MinoGuard
  • Class Antipsychotics; Neuropsychotherapeutics; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Schizophrenia

Highest Development Phases

  • Suspended Schizophrenia

Most Recent Events

  • 31 Jan 2014 Phase II development is ongoing in Israel, UK and Japan
  • 30 Nov 2011 MinoGuard has been acquired by XTL Biopharmaceuticals
  • 25 Mar 2011 XTL Biopharmaceuticals agrees to acquire MinoGuard
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top